Phathom initiates Phase 3 registrational study of VOQUEZNA for non-erosive GERD
Phathom Pharmaceuticals announced initiation of a registrational Phase 3 study of VOQUEZNA (vonoprazan) for as-needed treatment of non-erosive GERD.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.